Weekly Digest Nr 19 | Week 22 | 27-31/05/2024

ANTIMICROBIAL RESISTANCE AND ONE-HEALTH IN THE EU

HEALTH POLICY NEWS

■ WHO:

- Member States agree to share outcomes of historic IHR, pandemic agreement processes to World Health Assembly
- New resolution on antimicrobial resistance to mobilize action
- **European Commission** approves an <u>increase of the EU financial contribution to GlobalHealthEDCTP3 of</u> €110 million.
- Global Antibiotic Research & Development Partnership (GARDP) and the Stop TB Partnership's Global Drug Facility (GDF) - New partnership to improve access to new antibiotics in low- and middle-income countries to boost efforts to combat TB and AMR

SCIENTIFIC PUBLICATIONS

- **CMI** Which trial do we need? Gown and glove use versus standard precautions for patients colonised or infected with MRSA or VRE
- American Journal of Infection Control Effectiveness of a sodium hypochlorite isotonic solution in decolonization of patients with Candida auris: Learnings from a county health care system
- **Frontiers in Microbiology** <u>Antimicrobial peptides and their druggability, bio-safety, stability, and</u> resistance
- **Nature -** A Gram-negative-selective antibiotic that spares the gut microbiome
- **BMC Human Genomics** <u>Assessment of nucleic acid extraction protocols for antibiotic resistance genes</u> (ARGs) quantification in aircraft wastewater
- **Eurosurveillance** <u>Large hospital outbreak caused by OXA-244-producing *Escherichia coli* sequence type 38, Poland, 2023</u>

PUBLIC HEALTH REPORTS

■ FAO:

- The International FAO Antimicrobial Resistance Monitoring (InFARM) system: <u>Manual for</u> implementation 2024
- Global technical consultation on the strategic framework for early warning of animal health threats
- **WHO** Infection prevention and control in-service education and training curriculum
- **ECDC** Framework for prevention of communicable diseases and related special health issues

HEALTH POLICY BRIEFS

- **Médecins Sans Frontières/Doctors Without Borders** <u>Antimicrobial Resistance Activity Report 2023</u>
- **EMA** Annual report highlights progress in science, medicines and health in 2023
- = Quadripartite:
 - Working Group on Youth Engagement for AMR <u>Youth Manifesto in preparation for the UN General</u>
 Assembly High-Level Meeting on AMR
 - Key Recommendations and Priorities for the 2024 UNGA High-Level Meeting on Antimicrobial Resistance (AMR)

CONFERENCES AND WEBINARS

ECDC - <u>Scientific webinar on vibriosis</u>, 19 June

Weekly Digest Nr 19 | Week 22 | 27-31/05/2024

ANTIMICROBIAL RESISTANCE AND ONE-HEALTH IN THE EU

- International Society of Antimicrobial Chemotherapy (ISAC) Antifungal resistance in Candida and Aspergillus: is the honeymoon over? 10 June
- = Access to New Medicines: A Push Towards Optimising the AMR Response, 5 June
- **European Observatory on Health Systems and Policies**, recordings available:
 - <u>'The socioeconomic drivers and impacts of Antimicrobial Resistance (AMR)'</u>
 - 'Strengthening the EU response to prevention and control of Antimicrobial Resistance (AMR)'
- **ESCMID/ASM** Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, 17-20 September, Porto, Portugal, <u>abstract submission open</u>
- Innovative Health Initiative Impact on antimicrobial resistance: the legacy of the COMBACTE projects, 31 May
- HaDEA/HERA Info session: open call for proposals EU4Health Annual Work Programme 2024, 29 May
- DG SANTE AMR One Health Network Meeting
 - Minutes of 29 February 2024
 - Minutes of 1 March 2024

REGULATORY NEWS

\equiv EC:

- Industrial policy: Council gives final approval to the net-zero industry act
- Medical devices: Council adopts new measures to help prevent shortages

TENDER PUBLICATIONS

- **HADEA** Multiple Framework Contracts in cascade for support services to the European Commission on gathering intelligence on priority threats and medical countermeasures <u>Extension deadline and opening</u> date
- EFSA Provision of support to EFSA in the remit of scientific data management activities and processes in following areas: Bioinformatics, Pesticides residues and pesticide active substances, Chemical contaminants, Food additives, Food Contact Materials, Food Composition, Veterinary Medicinal Products, Food Consumption surveys, Plant and animal health, Controlled terminology Extension of deadline for tendering

\equiv ECDC:

- External Quality Assessment of Antimicrobial Susceptibility Testing for Salmonella and Campylobacter: Lot 1 – AST EQA for Salmonella Enterica; Lot 2 – AST EQA for Campylobacter spp -Contract award notice
- Vaccine Effectiveness, Burden and Impact Studies (VEBIS) of COVID-19 and Influenza <u>Modification</u> notice

OPEN CONSULTATIONS

\equiv EC:

- online public consultation on the draft implementing act on the management of conflicts of interest in Health Technology Assessments, deadline 26 June.
- Antimicrobials for use in animals: list of substances banned and substances authorised, deadline 20
 June.
- Water4All public consultation survey for the Strategic Research and Innovation Agenda (SRIA), deadline 11 August

Weekly Digest Nr 19 | Week 22 | 27-31/05/2024

ANTIMICROBIAL RESISTANCE AND ONE-HEALTH IN THE EU

EHMA - <u>Survey on health system disruption by invasive pneumococcal disease</u>

TRAININGS

- **ECRAID** <u>training modules on adaptive clinical trial designs</u>
- \equiv **ESCMID**:
 - How I Manage Common Infectious Diseases in Older Adults, 20 June
 - Summer School, Utrecht, the Netherlands, 29 June 6 July 2024

APPLICATIONS

- ESCMID Expression of Interest to join ESGEM-AMR working group (ESCMID Study Group for Epidemiological Markers Antimicrobial Resistance Working Group) capture expert knowledge on the relationship between AMR genotypes and AST phenotypes in bacterial pathogens.
- US Biomedical Advanced Research and Development Authority (BARDA)'s Division of Research, Innovation, and Ventures (DRIVe) - Submissions for Innovations in Clinical Metagenomic Next-Generation Sequencing (mNGS) to Improve Diagnostics for Viral Pathogens - <u>Deadline Extended</u>

LEGAL NOTICE

- **RESINFIT** is financed entirely by Inserm and receives no external funding or sponsorship from private organizations.
- = RESINFIT cannot provide any guarantees and cannot be held liable for any errors, inaccuracies or incompleteness of any information given on this digest or by any other third party.
- = The views and opinions expressed by individual authors of articles, presentations or discussion/opinion papers etc. do not necessarily reflect those of RESINFIT.
- RESINFIT provides links to many websites created and maintained by third party public and/or private organizations. The presence of a link is not a RESINFIT endorsement of the site. Upon following a link to a third-party website, users are leaving RESINFIT and are subject to the privacy and security policies of the owners/sponsors of the third-party website(s). RESINFIT is not responsible for the information collection practices of external sites.